EYLEA®

EYLEA is a vascular endothelial growth factor (VEGF) inhibitor designed to treat retinal diseases that lead to vision impairment. Administered through intravitreal injections, EYLEA helps manage conditions such as wet age-related macular degeneration (AMD), diabetic macular edema (DME), and macular edema secondary to retinal vein occlusion (RVO). By inhibiting VEGF and other growth factors, EYLEA reduces abnormal blood vessel growth and fluid leakage, preserving vision and improving patient outcomes. With regular treatment, many patients experience significant stabilization or improvement in their vision.

Main Treatment Areas

• Wet Age-Related Macular Degeneration (AMD): EYLEA is commonly used to treat wet AMD, a leading cause of vision loss in older adults. It helps prevent abnormal blood vessel growth and fluid leakage that damage the macula, the part of the retina responsible for central vision.
• Diabetic Macular Edema (DME): In patients with diabetes, EYLEA treats macular edema by reducing fluid buildup in the retina, helping to prevent vision loss caused by swelling.
• Macular Edema Secondary to Retinal Vein Occlusion (RVO): EYLEA is effective in treating vision loss caused by fluid buildup and macular edema due to branch or central retinal vein occlusion.

Key Benefits

• Vision Preservation and Improvement: EYLEA helps prevent further vision loss and can improve visual acuity in patients with retinal diseases, allowing many to maintain or regain daily functioning.
• Long-Lasting Effects: EYLEA offers a longer treatment interval compared to some other therapies, with injections typically required every 8 weeks after the initial dosing period.
• Proven Efficacy: Clinical trials have shown that EYLEA is highly effective in reducing the progression of vision loss and improving visual outcomes in a majority of treated patients.
• Multi-Condition Treatment: EYLEA is versatile, treating a range of retinal conditions including AMD, DME, and RVO, making it a go-to treatment for various causes of macular degeneration and edema.

Safety Information

EYLEA® is generally well-tolerated, but it is important to be aware of potential side effects. The most common side effects include mild discomfort at the injection site, redness in the eye, and temporary visual disturbances. More serious but rare risks include retinal detachment, increased intraocular pressure, and infections within the eye (endophthalmitis).

Additional Important Considerations:

1. Initial Dosing Frequency: EYLEA® typically requires monthly injections (every 4 weeks) for the first 3 to 5 months, depending on the condition. After this phase, treatment frequency can be reduced to every 8 weeks.
2. Potential for Serious Side Effects: While uncommon, EYLEA® carries risks such as retinal detachment, increased intraocular pressure, or eye infection (endophthalmitis). Patients experiencing eye pain, redness, light sensitivity, or sudden vision changes should seek immediate medical attention.
3. Long-Term Commitment: EYLEA® is a long-term treatment, requiring ongoing injections to manage conditions such as wet AMD or DME. Regular follow-up appointments with an eye specialist are essential.
4. Contraindications: Patients with active eye infections or inflammation should avoid EYLEA® injections. Those with known allergies to aflibercept or its components should not use EYLEA®.

Consult with your healthcare provider to understand if EYLEA® is suitable for your condition and to assess any risks based on your medical history.

EYLEA Purchase Information

For healthcare professionals seeking to purchase EYLEA®, Dr Sales Direct is a reliable wholesale supplier offering competitive wholesale prices.  Sign in to access wholesale rates and bulk purchase options, ensuring you receive high-quality products at the best prices for your practice’s needs. Dr Sales Direct provides cost-effective solutions for ophthalmic treatments, helping you deliver the best care to your patients.